The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains ...
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...
An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...
Patients living with myelofibrosis who also experience anemia may see meaningful improvements in blood counts when treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback